| Management target | Revenue 17.5% FY27 |
|---|
| Revenue growth | 24.3% YoY consolidated growth. |
|---|---|
| Margins | Gross margin at 74.1%; EBITDA expanded to 32%. |
| Demand visibility | Strong momentum in preventive and insurance segments. |
| Management confidence | High; citing best-in-class turnaround times and operational efficiency. |
Growth
Standalone revenue rose 26.1%; pathology grew 26%. PAT at INR 51.3 Cr, up 34% YoY.
Outlook
Management maintains mid-to-high teen growth guidance for FY27; divesting radiology business; expansion into Africa.
Risks
Radiology segment remains dilutive to ROC; potential churn in new franchisee additions; pricing erosion in partnership panels.
Last quarter's promises, checked
Delivered
- Guided mid-to-high teen growth → delivered 24.3% (= BEAT)
- Guided 500 franchisees/qtr → delivered 900 (= BEAT)
- Guided 73-74% Gross Margin → delivered 74.1% (= BEAT)
Partly delivered
- Guided 15% volume growth → delivered 28% but with price erosion (= PARTIAL)
Missed
- Guided 34% EBITDA margin → delivered 32.2% (= MISS)
Earnings Call Transcript filed with BSE, NSE: THYROCARE. Summary written with AI assistance from the document.
Thyrocare Technologies Ltd: key numbers
- Share price
- ₹566.85
- Market cap
- ₹9,022 Cr
- Revenue (annual)
- ₹829.0 Cr
- Net profit (annual)
- ₹163.0 Cr
- P/E (TTM)
- 51.2×Sector 57.8×
- Promoter holding
- 60.92%+0.00% QoQ
- FII holding
- 5.43%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Thyrocare Technologies Ltd
All →Thyrocare Technologies Employee Stock Options
Thyrocare Technologies Limited has granted 1,92,000 employee stock options to eligible employees under the company's approved stock option scheme.
Thyrocare Technologies Merger & Restructuring Worth ₹141.4 Cr
Thyrocare's board approved sale of 100% in Nueclear Healthcare to Trovera for ~₹141.40 Crore. The move exits radiology to refocus on core pathology business.
- Value
- ₹141.4 Cr
- Execution
- On or before November 30, 2026
Thyrocare Technologies Share Pledge
API Holdings, successor to promoter Docon, released a full pledge over 7.95 crore Thyrocare shares after NCD redemption. No Docon shares remain encumbered.
Thyrocare Technologies Acquisition
API Holdings Limited reported an exempt acquisition of 8.12 crore shares (51.02%) of Thyrocare Technologies Limited, pursuant to the amalgamation of Docon Technologies Private Limited.
Thyrocare Technologies Promoter Buying (Off-Market)
API Holdings acquired 8,12,00,000 shares (51.02%) of Thyrocare Technologies via a NCLT-approved scheme of amalgamation. The transfer resulted from the merger of Docon Technologies into API Holdings.
- Promoter stake change
- +51.02%
Thyrocare Technologies Investor Presentation: Key Takeaways
Thyrocare delivered strong Q1 FY27 results with 24% YoY consolidated revenue growth and 34% YoY PAT growth, driven by pathology network expansion and high-value specialty test launches.
- Call
- Guides 20% growth